What is MaxCyte's stock issuance proceeds?

MaxCyte (MXCT) reported stock issuance proceeds of $5K in Q1 2026.

How has MaxCyte's stock issuance proceeds changed year-over-year?

MaxCyte's stock issuance proceeds decreased by 98.7% year-over-year, from $383K to $5K.

What is the long-term trend for MaxCyte's stock issuance proceeds?

Over 3 years (2022 to 2025), MaxCyte's stock issuance proceeds has grown at a -46.9% compound annual growth rate (CAGR), from $2.89M to $432K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

MaxCyte MXCT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Bio-Rad LaboratoriesBIO

$3.4M-20.9%

Immix Biopharma, Inc.IMMX

$33.53K—

Rapid Micro BiosystemsRPID

$140K+55.6%

PDE

Pro-Dex, Inc.PDEX

$44K+63.0%

RepligenRGEN

$0-100%

TEC

Bio-TechneTECH

$29.96M+101%

Other financials

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

See full

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's stock issuance proceeds?: MaxCyte (MXCT) reported stock issuance proceeds of $5K in Q1 2026.
How has MaxCyte's stock issuance proceeds changed year-over-year?: MaxCyte's stock issuance proceeds decreased by 98.7% year-over-year, from $383K to $5K.
What is the long-term trend for MaxCyte's stock issuance proceeds?: Over 3 years (2022 to 2025), MaxCyte's stock issuance proceeds has grown at a -46.9% compound annual growth rate (CAGR), from $2.89M to $432K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.